Fig. 2

A Schematic overview of the STOP trial: a 4 week run-in, followed by either an intervention period or a control period of 14 weeks, followed by a crossover. After completion of both treatment periods, patients may choose to participate in the extension study. B All patients will be enrolled with a prescription of Fluticasone 1000 mcg and Salbutamol 100 ug (as needed). C Patients receive a stable dose of ICS during the control period. D During the intervention period, patients half the dose of Fluticasone every 2 weeks. Patients will discontinue ICS after 4 weeks and remain ICS naïve for 10 weeks